X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the merger, the company will focus on advancing Oruka’s pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) for the treatment of plaque psoriasis.
Lead Product(s): ORKA-001
Therapeutic Area: Dermatology Product Name: ORKA-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oruka Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger April 03, 2024
Details:
This clinical trial used a 1:1:2 randomization between lower dose rNAPc2, higher dose rNAPc2 and standard of care heparin that was delivered in prophylactic doses in 93% of the patients. rNAPc2 patients received three sub-cutaneous (SC) doses.
Lead Product(s): Recombinant Nematode Anticoagulant Protein c2
Therapeutic Area: Infections and Infectious Diseases Product Name: rNAPc2
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
In a GENETIC-AF Phase 2b clinical trial, the prevalence of bradycardia was significantly lower for Gencaro compared to metoprolol. Gencaro, is an investigational, pharmacologically unique beta-blocker for the treatment of atrial fibrillation in heart failure patients.
Lead Product(s): Bucindolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Gencaro
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
rNAPc2 (AB201) is a small recombinant protein being developed as a potential treatment for COVID-19 and potentially other viral diseases and a potent, selective inhibitor of tissue factor (TF).
Lead Product(s): rNAPc2
Therapeutic Area: Infections and Infectious Diseases Product Name: AB201
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
Details:
Recombinant nematode anticoagulant protein c2 (rNAPc2) is a novel and potent inhibitor of fVIIa/TF that may improve current therapeutic strategies used in COVID-19.
Lead Product(s): rNAPc2
Therapeutic Area: Infections and Infectious Diseases Product Name: AB201
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
Details:
rNAPc2 is a recombinant protein therapeutic being developed by ARCA as a potential treatment for COVID-19 and other severe viral infections. Deal provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID-19 and other indications.
Lead Product(s): Recombinant Nematode Anticoagulant Protein c2
Therapeutic Area: Infections and Infectious Diseases Product Name: rNAPc2
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: University Medical Center of Johannes Gutenberg University Mainz
Deal Size: $1.9 million Upfront Cash: Undisclosed
Deal Type: Agreement July 07, 2021
Details:
AB201 is the only novel compound being developed for COVID Associated Coagulopathy. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020.
Lead Product(s): AB201
Therapeutic Area: Infections and Infectious Diseases Product Name: rNAPc2
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
ARCA anticipates initiating a Phase 2b/3 sequential clinical trial, ASPEN-COVID-19, of AB201 in approximately 100 patients hospitalized with COVID-19 in the fourth quarter of this year, with Phase 2b followed by a contiguous Phase 3 study that is dependent on Phase 2 results.
Lead Product(s): rNAPc2
Therapeutic Area: Infections and Infectious Diseases Product Name: AB201
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
AB201 is a small recombinant protein and a potent, selective inhibitor of tissue factor, developed as a potential treatment for RNA virus- associated disease, initially focusing on COVID-19.
Lead Product(s): rNAPc2
Therapeutic Area: Infections and Infectious Diseases Product Name: AB201
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
The FDA provided feedback for ARCA's clinical development plans for evaluating AB201 as a potential treatment for patients with severe COVID-19.
Lead Product(s): rNAPc2
Therapeutic Area: Hematology Product Name: AB201
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
